XIAP and prostate carcinoma: A XIAP inhibitor called Embelin has been shown to have anti-tumor effects such as inhibition of cell proliferation and induction of apoptosis in vitro experiments using osteosarcoma cells [21], prostate cancer cells [22], and pancreatic cancer cells [23].